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ABSTRACT: Drug-induced proarrhythmia is so tightly associated with prolongation of the QT interval that QT prolongation has become widely accepted as a surrogate marker for arrhythmia. The problem is that QT interval as an arrhythmia indicator is too sensitive and not selective, resulting in many potentially useful drugs eliminated early in the drug discovery process. We first set out to predict the fundamental mode of binding for the proarrhythmic drug dofetilide with the promiscuous cardiac drug target, the hERG potassium channel. In a novel linkage between the atomistic and functional scales, computed binding affinities and rates from atomistic simulation are utilized here to parameterize function scale kinetic models of dofetilide interactions with the hERG channel. The kinetic model components are then integrated into predictive models at the cell and tissue scales to expose fundamental arrhythmia vulnerability mechanisms and complex interactions underlying emergent behaviors. Human clinical data from published studies were used to validate model framework and showed excellent agreement, demonstrating feasibility of the approach. The model predictions show that a clinically relevant dose of dofetilide increased arrhythmia vulnerability in all emergent TRIaD-linked parameters including Triangulation, Reverse use-dependence, beat-tobeat Instability and temporal and spatial action potential duration Dispersion. Application of machine learning demonstrated redundancy in the TRIaD linked parameters and suggested that changes in beat-to-beat instability were highly predictive of arrhythmia vulnerability in this setting. Here, we demonstrate the development and validation of a prototype multiscale model framework to predict electro-toxicity in the heart for the proarrhythmic drug dofetilide from the atom to the rhythm. Keywords: computational model, hERG, safety pharmacology, multiscale, druginduced cardiotoxicity SIGNIFICANCE STATEMENT: Cardiotoxicity in the form of deadly abnormal rhythms is one of the most common and dangerous risks for drugs in development and clinical use. There is an urgent need for new approaches to screen and predict the effects of chemically similar drugs on the cardiac rhythm and to move beyond the QT interval as a diagnostic indicator for arrhythmia. To this end, we present a computational pipeline to predict cardiotoxicity over multiple temporal and spatial scales from the drug chemistry to the cardiac rhythm. We utilize predicted quantitative estimates of ion channel-drug interactions from our companion paper to simulate cardiotoxicity over multiple temporal and spatial scales from the drug chemistry to the cardiac rhythm.
INTRODUCTION:
Cardiotoxicity is one of the most common reasons for drug removal from the market, typically manifesting as prolongation of the QT interval on the ECG with the potential for fatal ventricular arrhythmias (1). In the context of drug induced cardiac arrhythmia, the vital hindrance to prevention of electrical rhythm disturbances is a lack of meaningful approaches to distinguish between therapeutic, benign or harmful actions of drugs.
An important example is the use of QT interval prolongation as a surrogate marker for proarrhythmia (2). Since 2005, the regulatory process for preclinical drug candidates includes a dedicated clinical study in healthy volunteers, the so-called "Thorough QT Study" (TQT) (3). A drug that results in greater than 5 ms QT prolongation above normal in healthy humans indicates "regulatory concern" (4).
The problem is that many useful drugs that were approved prior to the 2005, including the commonly used antiarrhythmic agents verapamil, ranolazine and amiodarone to name a few, all fail the TQT -they all block K + -selective cardiac channel hERG and prolong QT interval (5-7). Indeed, there exist numerous examples of safe and effective drugs (including antiarrhythmics, antipsychotics and antibiotics) that gained FDA approval prior to TQT implementation (1, 2, 8) . If screened today, these safe drugs would fail the test.
Abnormal cardiac electrical activity is most often a side effect from unintended block of the promiscuous drug target hERG, the delayed rectifier K + channel in the heart. hERG block results in prolongation of the QT interval on the ECG, a phase of the cardiac cycle that corresponds to ventricular repolarization.
Not all hERG block is proarrhythmic. But, at present, there is no accurate method to distinguish unsafe hERG blockers from safe drugs. There are at least two distinct classes of hERG blockers that prolong QT interval (1): In the first group are drugs that block hERG, prolong QT interval and increase proclivity to potentially deadly torsades de pointes (TdP) arrhythmias. This group includes, for instance, sotalol, dofetilide, and cisapride (9, 10). The second group consists of hERG blockers that prolong QT interval and have low risk for ventricular arrhythmias like ketaconozole, moxifloxacin, amiodarone, and verapamil (11-16).
There have been many attempts to distinguish the two classes of hERG blockers via "top-down" approaches including studies devoted to analytical methods aimed at assessing the relationship between rate corrected QT "morphology" and arrhythmia risk (17) (18) (19) (20) . More recently, the Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative comprising a worldwide team of regulators, academicians and industry scientists have worked to develop and validate a collection of nonclinical assays to move beyond the thorough-QT study and better predict preclinical arrhythmia risk (21).
This program promotes screening of additional cardiac ion channel targets and assessing net impact on the cellular action potential duration and QT interval via in vitro experiments and in silico functional models. While the consideration of multi-channel block is an improvement, even these newer computational models still generally rely on
IC 50 values as model inputs, exclude non-ionic drug targets and rely on prolongation of the action potential duration or QT interval as the marker for safety (22) (23) (24) (25) (26) . Moreover, although these methods have shown to be fairly effective at categorizing risk for the CiPA test compounds, there has not yet been mechanistic validation of the accuracy of the model prediction. In other words, a test drug may land in the right category, but for the wrong reason. The in silico assay currently cannot distinguish between chemically similar drugs with similar affinity profiles. Moreover, incorporating individual genetic differences into the current model schema is not yet possible. Finally, there are a variety of drugs that do not appear to exhibit multichannel block, but rather hERG block alone with low arrhythmia risk such as moxifloxacin, ketaconozole and the selective-serotonin reuptake inhibitor 27) .
We hypothesized that channel conformation state specificity and the associated kinetics of hERG block may promote TdP as indicated by the TRIaD: Triangulation, reverse use dependence, beat-to-beat instability of action potential duration, temporal and spatial action potential duration dispersion (9, 28, 29) . Here, we use an integrative experimental and computational modeling and machine learning approach that spans scales from the atom to the cardiac rhythm to predict the intrinsic properties of the structure-activity relationship that determine proarrhythmia for the prototype drug dofetilide, which is a potent hERG blocker, prolongs QT interval and has a high risk for
TdP arrhythmias (30, 31). Thus, it was chosen as an ideal candidate for our proof-ofthe-concept study.
In this study, we take the first necessary steps to answer the question, "Can we predict when a QT prolonging drug is a proarrhythmic drug based its chemistry?" We have assembled a proof of concept multiscale model for predictive cardiac pharmacology. We present a novel multiscale approach based on structural and dynamic atomistic models of drug-channel interactions and kinetics intended to predict drug-induced arrhythmia.
We expect that the model framework may be expanded to make an impact in drug discovery, drug safety screening for a variety of compounds and targets, and in a variety of regulatory processes. We propose that the potential added value in this method is that it can be expanded to incorporate a variety of additional drug targets to glean binding affinities at the atomic scale, and the structural models can be extended to include genetic mutations, polymorphisms or variants of unknown significance that may impact drug binding. The method can be also used to distinguish between chemically similar drugs that may appear to have similar effects on the action potential and QT interval.
Materials and methods

Structural modeling of hERG
The wild-type drug-free atomistic structural hERG model, shown in 
Dofetilide-hERG interaction function scale model
The wild-type drug-free hERG Markov model previously described in (32) is shown in Figure 1D . To simulate drug interactions with hERG, we used simulated affinities, (i.e. drug dissociation constants) K D , and drug diffusion rates, D, both computed from the umbrella sampling (US) molecular dynamics (MD) simulations used to constrain the drug "on" (k o_d and k od ) and "off" (r o_d and r od ) model transition rates for open state ( Figure 1D -bottom). There are two modes of drug bound channel states -neutral (green) and charged (red). The charged and neutral drug fractions, f 1 and f 0 , are calculated using the following equations:
Where pH = 7.2 and pK a = 7.0 (33, 34). 
Computed dofetilide concentrations
We used the population C max (maximum plasma concentration) of dofetilide: 2.72 ng/mL (33), and converted it to nanomolar (nM) concentration (
in the models, where 441.567 g/mol is dofetilide molar mass.
Simulation of TRIaD in dofetilide and control case in O'Hara-Rudy Human model
First, action potential duration (APD) Triangulation was calculated as the repolarization time from APD 30 to APD 90 from 1000 simulated cells with application of noise current.
The noise current was calculated using the equation from (36),
where n is a random number between 0 and 1 from a Gaussian distribution, and Δt is the time step.
3) is the diffusion coefficient, which defines the amplitude of noise (36). The noise current was generated and applied to the membrane potential V t throughout the simulated time course. Reverse-use-dependence was measured as APD 90 at steady state for each pacing cycle length (from 2 Hz to 0.5 Hz), and APD adaptation curves were constructed. Beat-to-beat (bTb) Instability was simulated by applying small amplitude inward currents randomly between -0.1 to -0.2 pA/pF for 50 ms over the course of the action potential plateau between 10 to 700 ms at 1 Hz for 1000 beats.
Fiber simulations
We simulated a transmural fiber composed of 165 O'Hara-Rudy human ventricular cells (37) (Δx = Δy = 100 μm) connected by resistances to simulate gap junctions (38). The fiber contains an endocardial region (cells 1 to 80) and epicardial region (cells 81 to 165), which showed a linear decrease in APDs (39, 40) . G Kr was monotonically increased from 0.04 to 0.05. The heart was paced at 1 Hz to match the clinically observed QT intervals ~400 ms (41-43). AP simulations were carried out in epi/endocardial cells by changing various ion channel conductances (37). The stimulus is applied to the first cell.
The fiber was paced at varying cycle length from 800 to 1400 ms for 200 beats (mean heart rates = 61 bpm) in order to match the clinical data (56.8േ6.4 bpm) (33). Pseudo
ECGs were computed from the transmembrane potential V m using the integral expression as in Gima and Rudy (44) . Heart rate corrected QT (QTc) was computed using Fridericia formula using the cubic root of RR interval (45).
Spatial APD dispersion was measured using the T-wave area indicator, which was calculated as the T-wave amplitude on the computed pseudo-ECGs. For this purpose, a 1-dimensional model of the transmural wedge preparation, as described in (5), was stimulated by applying a standard short-long protocol as follows: The transmural wedge preparation was stimulated by a train of pulses (S1) at 1 Hz pacing rate until the steadystate was reached followed by a premature beat (S1-S2 interval = 800 ms) and then a delayed beat (S3) was delivered after a long pause (S2-S3 interval = 5000 ms). T-wave area calculations were computed as follows:
where Δ t ൌ 1 ms, t 1 is the time where ECG equals to T peak -0.9*(T peak = minimum of left side of T wave), and t 2 is the time where ECG equals to T peak -0.9*(T peak = minimum of right side of T wave).
Frequency-dependent QT prolongation
The fiber was paced at 1Hz for 1000 beats (S1) and then a second stimulus (S2) was applied after a varying RR interval (between 550 and 1200 ms). The QT interval, in response to S2, was recorded. The same simulations were carried out 6 times for both control and 2.72 ng/mL dofetilide with noise currents, and the relative changes in slope of relationship of QT and preceding RR intervals were calculated.
Two-dimensional simulations
2D simulations were performed to determine if proarrhythmic phenomena observed in lower dimensions cause reentrant arrhythmias. Current flow is described by the following equation:
where V is the membrane potential, x and y are distances in the longitudinal and transverse directions, respectively, D x and D y are diffusion coefficients in the x and y directions. We simulated a heterogeneous and a homogenous cardiac tissue on a 500
by 500 pixel grid with Δx = Δy = 100 μm. The heterogeneous tissue contains an endocardial region (fibers 1 to 180) and epicardial region (fibers 181 to 500). We also incorporated anisotropic effects by setting D x and D y such that the ratio of conduction velocities is 1:2 (46). A typical S1-S2 protocol was used for Figure 5 . The tissue was first paced (S1) in a 0.5 cm × 1.1 cm area on the left edge of the endocardial region, and a premature stimulus (S2) was then applied in a 1.8 cm × 1.5 cm area on the top left corner of the endocardial region. Small amplitude inward currents were randomly applied between -0.1 to -0.45 pA/pF on each cell in both heterogeneous and homogenous tissues after 0.5 ms.
Action potential duration (APD) mapping
We reconstructed the "human transmural myocardial wedge" based on data describing transmural action potential heterogeneity mapped from normal human left ventricle (40) ( Figure 6A ). First, the O'Hara-Rudy human model (37) was used to generate a G Kr lookup table corresponding to APD 80 . Next, experimental 2D APD 80 map (100 x 100 - Figure 6A ) was used to create a 2D G Kr map using the G Kr lookup table. Then the twodimensional G kr values (100x100) were used to simulate APD 80 at pacing rate of 0.5 Hz.
We then constructed 3D wedge of 100 by 100 by 1 cells with Δx = Δy = 200 μm and Δz = 500 μm using this APD mapping data. Current flow is described by the following equation:
Where V is the membrane potential. D x , D y and D z are diffusion coefficients in the x, y and z directions. Stimulus current I stim is 150 mA/cm 2 for 0.5 ms. We also incorporated anisotropic effects by setting D x , D y and D z such that the ratio of conduction velocities is 2:4:1 (46).
Local sensitivity analysis
We calculated elasticity coefficients (sensitivities) for arrhythmia vulnerability parameters from the TRIaD based simulations. The protocol for arrhythmia vulnerability parameters from the TRIaD based simulations is the same as in Figure The transmural fibers were stimulated by a standard short-long protocol, and T-wave areas were calculated (as described in Fiber simulations) from 1000 cases with noise currents.
Random forest machine learning algorithm
We applied a multivariate correlation-based filter selection (CFS) technique using a random forest machine learning algorithm for multiclass classification (49) Random forest is an ensemble decision tree, which contains a collection of single decision trees. Each tree is built over random extraction of the observations from the dataset and the random extraction of the features (arrhythmia vulnerability parameters in this case) (51). For each feature a series of questions are formulated so that the answer to those questions lead to the best possible separation of classes into groups that contain only one class or the majority of one class at each node. Therefore, the importance of each feature is indicated by purity in each branched out node, and impurity within a node for a particular feature indicates reduced importance. The importance of each feature is averaged across all the trees in random forest classifier to determine the final importance of the features (52).
In order to train the random forest classifier, we first performed feature scaling using Eq.
[9] to assure that each feature in the dataset has zero-mean and unit-variance (53)
After feature scaling, we split our dataset into random training and testing subsets (using 80% of data for training and 20% of data for testing the performance of the trained classifier). Then we trained the random forest multiclass classifier using the training subset and set 10 trees and entropy at the same time as the measure of impurity for the random forest classifier. Entropy is a measure that controls how the decision tree decides which feature to choose first and where to split the data (Eq.
[10]).
Where the ܲ is the fraction of examples in class i.
RESULTS
The first step we took to build a computational pipeline for predictive cardiac safety These values allowed for the constrained optimization of rate constants that were used to populate a state dependent hERG function scale model shown schematically in Figure 1D . To simulate drug interactions with hERG, we used drug diffusion rates D (~0.11×10-6 cm2/s and ~0.15×10-6 cm2/s for neutral and charged) and affinities (dissociation constants K Do , Figure 1C Figure 1D (bottom). In both experiment and simulations ( Figure 1E ), peak I Kr was recorded at the end of the 3-s activating step to 0 mV with drug concentrations from 0 to 7.5 ng/mL. Percentage of drug block was calculated by (I control -I drug )*100/I control and compared to experimental data (33), demonstrating good fit ( Figure 1E ).
Fig. 2
Next, we subjected our computational pipeline for safety pharmacology to a validation test using the gold standard data: human clinical data in the form of electrocardiograms in the absence and presence of dofetilide. To do so, as shown schematically in Figure   2A , we incorporated the function scale model of dofetilide interaction with the hERG channel ( Figure 1D ) into the O'Hara-Rudy human cardiac ventricular myocyte model and then extended this model to construct a one-dimensional strand of O'Hara-Rudy cells (37) by connecting them via simulated resistive elements to represent gap junctions. We applied a simulated stimulus current at one end to initiate a propagating one-dimensional wave at the clinically reported heart rate between 43 and 75 beat per minute (bpm) (33). Figure 2B shows the calculation of the spatial and temporal gradients of electrical activity used to construct a heart rate corrected pseudo ECG (QT C interval) for a range of dofetilide concentrations. Finally, as shown in Figure 2D , we simulated QT intervals over a wide range of preceding RR intervals after 2.72 ng/mL dofetilide application and compared to the clinically observed changes (9). Each cell in the simulated tissue was subjected to a physiological noise current in order to introduce physiologically relevant variability. Rate dependent changes in the QT interval were tracked as the slope of the linear regression line estimating the QT -√ R R relation. Again, the predicted relationship falls within the range of clinical data, indicating that the model can reproduce rate dependent changes in drug-induced QT interval.
Fig. 3
We next carried out computational screening in O'Hara-Rudy human computational ventricular myocytes for the effect of dofetilide to promote proarrhythmia by tracking the parameters comprising the TRIaD. We tracked each parameter in the absence of drug (control conditions in black) and in the presence of average patient plasma concentration of 2.72 ng/mL dofetilide (red). This approach was also carried out in simulated rabbit ventricular myocytes to explore the effects of species differences. The predicted results in rabbit were very similar to human and are shown in Supplemental Figure S1 .
In Figure 3A , temporal APD dispersion was quantified in a cell population of 1000 individual simulated cardiac myocyte action potentials constructed by incorporating physiological noise (36, 54, 55) . APD temporal dispersion was quantified as the difference between the maximum and minimum APD. Dofetilide within the clinical dosing range has a clear effect to promote temporal APD variability in the presence of the drug (Control -47 ms; 2.72 ng/mL Dofetilide -78 ms). Figure 3B illustrates the effect of dofetilide to promote triangulation of the action potential as a function of APD prolongation. In the absence of drug, control cells had a slope of 0.25, while 2.72 ng/mL Dofetilide increased the slope to 0.66. Figure 3C shows Poincaré plots of sequential APD pairs indicating beat-to-beat instability following the application of small electrical perturbations in the absence of drug or with 2.72 ng/ml dofetilide.
Instability was assessed by applying small amplitude inward currents randomly between -0.1 to -0.2 pA/pF for 50 ms over the course of the action potential plateau at a basic cycle length of 1000 ms. In Figure 3D , reverse use dependence induced by dofetilide was evaluated. The action potential adaptation curves were generated using 
Fig. 5
We next set out to test the effect of dofetilide in the setting of extrasystolic excitable triggers in the heterogeneous tissue as shown in Figure 5 . Again, in the presence of spatial noise to promote low-level electrical instability, when 2D tissue was simulated using a typical S1-S2 protocol (56, 57), 2.72 ng/ml dofetilide application resulted in considerable dispersion of repolarization that was absent in control drug free tissue. The tissue was first paced (S1) (first panel) in a 0.5 cm × 1.1 cm area on the left edge of the endocardial region, and a premature stimulus S2 (third panel) was then applied in a 1.8 cm × 1.5 cm area on the top left corner of the endocardial region. As described above, spatial heterogeneity was applied via small amplitude inward currents randomly applied between -0.1 to -0.45 pA/pF to each cell in heterogeneous tissues after 0.5 ms. Time snapshots (panels) with voltage gradients indicated by the color map are shown in Fig.   5 . These maps were constructed following the last planar wave (S1) (first panel) and throughout termination of the most persistent wave after S2 stimulus (last panel). The corresponding action potentials from three points in space are shown in the right panels.
In the absence of drug (top row), there was no persistence of electrical instability. In the bottom row the effect of dofetilide is shown, which reproducibly (n = 5 simulations) promoted numerous persistent arrhythmia triggers observed as afterdepolarizations in the cellular action potentials (right).
Fig. 6
We eveloped an in silico left ventricular (LV) 3D wedge reconstruction of the human cardiac tissue based on the experimental data from Glukhov et al. (40) for the drug free case and with 2.72 ng/ml dofetilide applied. Clinical and experimental data suggest that male and female subjects respond differently to dofetilide intervention, with females exhibiting increased sensitivity and proclivity to abnormal rhythm (58-60). The LV wedges were paced at basic cycle of 1000 ms for 5 beats with small amplitude inward currents randomly applied between -0.1 to -0.45 pA/pF to each cell after 0.5 ms. The model simulations show drug-induced QT interval prolongation both in male and female.
However, in females, dofetilide caused considerably larger prolongation of the QT interval, at 60 bpm, as well as at 80 bpm.
Fig. 7
In order to assess the specific drug -channel interactions that comprise the dofetilide structure-activity relationship and the link to proarrhythmia, we undertook sensitivity analysis to determine how sensitive the arrhythmia vulnerability parameters from the TRIaD based simulations are to our underlying model parameters ( Similarly, in Figure 7B , simulated beat-to-beat instability of action potentials (average and standard deviation of APD 90 for each rate perturbation are shown) with respect to transition rate changes are demonstrated. And Figure 7C shows relative changes in transition rates with respect to the APD 90 at a slow pacing rate, which reflect maximal reverse use dependence (BCL = 2000 ms). Again, binding and unbinding rate parameters of neutral drug (green bars) for inactivated channel state caused more changes in the model outputs compared to other parameters, but the model outputs are still relatively insensitive. Finally, Figure 7D , shows higher elasticity values of the Twave area to neutral drug (green bars) binding and unbinding rates for inactivated state.
However, the analysis showed that the model was robust to perturbations (elasticity value < 1).
Fig.8
Finally, we used random forest machine learning algorithm to evaluate the importance of each arrhythmia vulnerability parameter from the TRIaD (APD TRI, bTb instability, Twave area and RUD) to determine the final target classification (control versus drug affected at different dofetilide doses). In general, to make a good classification algorithm it is important to identify parameters that are correlated with the target output of interest but uncorrelated among themselves. Therefore, we used Pearson's correlation coefficient (see methods) to explore the linear dependence of TRIaD parameters in Figure 8A . If two TRIaD parameters are highly correlated, they provide redundant information. As shown in Figure 8A , all TRIaD parameters are highly correlated. After finding highly correlated features, we constructed a multiclass random forest classification (see methods) using all the correlated TRIaD parameters. The random forest classifier outputs the importance of all TRIaD parameters and indicates the importance of each parameter to correctly predict the target (drug free, or low, medium or high risk (indicated by dose)). Figure 8B suggested that beat-to-beat (bTb) instability is the most important feature that contributes to classify control case versus drug affected case. Figure 8C illustrates the multiclass classified region for control, dofetilide 0.1 ng/mL, dofetilide 1 ng/mL and dofetilide 2.72 ng/mL using bTb instability and RUD with random forest classification's accuracy of 93%. Please have Parya respond to Igor's comment
A major factor plaguing drug development is that there is no preclinical drug-screening tool that can accurately predict unintended drug induced cardiac arrhythmias from chemically similar drugs. The current approaches rely on substitute markers such as action potential duration or QT interval prolongation on the ECG. Unfortunately, QT prolongation is too sensitive and not specific in its indication of likelihood of arrhythmias.
There is an urgent need to identify a new approach that can predict actual proarrhythmia from the drug chemistry rather than relying on surrogate indicators.
In this study we take the first steps to construct a computational pipeline for predictive safety pharmacology. The goal of this study was to develop a framework that will allow the detection of unsafe hERG blockers from their drug chemistry early in the preclinical screening process. Thus, we have assembled the process and utilized clinical data to demonstrate the utility for a proof-of-concept multiscale computational model to predict cardiac effects of dofetilide, a potent hERG blocker with a high pro-arrhythmia risk.
We began by developing physics based computer models ( Interestingly, our previously published models required higher doses of dofetilide to cause prolongation of the QT interval (32), but the model generated from the molecular dynamics generated parameters in this study was able to reproduce dose-dependent prolongation of the QT interval in very close agreement to the clinical data ( Figure 2B ).
These results serve as an important reminder for the difficulty in empirically deconstructing state-dependent drug mechanisms from experimental data. This is because the drug interaction often occurs on the same timescale (ms) as channel gating. In the physics-based approach that we used, the channel is held in a static conformation, allowing for an unambiguous calculation of drug-channel affinity for discrete channel conformations.
Computational ion channel structure to function relationship
In this study we have attempted to make a novel link between ion channel structure and function. We utilized atomic scale predictions to inform rate constants for constructing computational channel-scale kinetic models for dofetilide interaction with hERG channels. Potential mean force calculations from drug -channel binding molecularstructure level trajectories allowed for the calculation of dissociation constants K D for dofetilide interactions with hERG for the open state of the channel. These simulated data combined with predicted diffusion coefficients from the same atomistic MD runs allowed for drug "on" and "off" rates to discrete states to be introduced into the function scale Markov model of hERG.
Connection between structure -activity relationship and proarrhythmia
Computational models of dofetilide interaction with the hERG receptor were integrated into virtual cardiac cell and tissue level models to predict emergent drug effects to promote elements of the TRIaD: Triangulation, reverse use dependence (increase in drug effects at slow heart rates), beat-to-beat instability of action potential duration, temporal and spatial action potential duration dispersion -proarrhythmia markers that emerge at cell and tissue scales.
The driving hypothesis underlying the goals of this study is that the proarrhythmic cellular manifestations of the TRIaD arise directly from the underlying kinetics of channel block. Identification of the specific State-dependent kinetics of drug blockade that give rise to components of the TRIaD is essential to define new standards for preclinical compounds that can be used to rule out compounds with these properties in early screening tests. Our sensitivity analysis (Figure 7 ) suggests that as a general principle, reducing the affinity of hERG blocking drugs to the inactivated state will reduce the propensity to arrhythmias linked to TRIaD mediated arrhythmia vulnerability parameters. The sensitivity analysis suggests that the model was highly robust to small perturbations in the model parameters. that all TRIaD parameters are highly correlated, which indicates that there is no need to track them all because they contain redundant information. Given this outcome, we employed a multiclass random forest classification machine learning algorithm using the correlated TRIaD parameters to determine the relative importance of each TRIaD parameter to correctly predict whether a simulated cell belongs to the drug free, or low, medium or high risk category (indicated by dose in this study). Other drugs can be compared to dofetilide outputs to indicate risk relative to the high-risk drug dofetilide.
The beat-to-beat (bTb) instability parameter was shown to be most important feature in classifying the drug safety.
In this study, we have brought together model simulations at the atomistic level for hERG channel structure, dynamics and channel -drug interactions as well as simulations at the functional levels of the protein, cell and tissue. states by increasing and decreasing each rate at ±20% for neutral (green) and charged
